Quizartinib: a new treatment for FLT3-ITD-positive acute myeloid leukemia

Quizartinib (Quizartinib), trade name Vanflyta, is an innovative drug targeting FLT3-ITD mutation-positive acute myeloid leukemia (AML). AML is a malignant tumor derived from bone marrow hematopoietic stem cells, and FLT3-ITD mutation is considered a common and important molecular marker in AML, which is usually closely related to poor prognosis, high recurrence rate, and shorter survival.

The mechanism of action of Quizartinib is to precisely inhibit the activity ofFLT3 receptor, blocking the abnormal signaling pathway caused by FLT3-ITD mutation. This intervention effectively prevents the proliferation and survival of leukemia cells, making quizartinib one of the important drugs for the treatment of FLT3-ITD-positive AML.

The drug was developed by Japan's Daiichi Sankyo Company and quickly gained widespread attention and recognition from the international medical community. Quizartinib was first approved for clinical use in Japan in October 2019, and was subsequently approved by the US FDA in July 2023 and will be launched in the EU in November 2023. This series of approvals shows that the significant efficacy and safety of quizartinib in the treatment of FLT3-ITD-positive AML have been verified by authoritative institutions.

The recommended use of quizartinib is once-daily oral administration, with the specific dose adjusted based on the patient's weight, tolerance and individualized treatment plan. During the initial treatment phase, patients may need to take it in combination with other medications to enhance the effectiveness of the treatment. However, the use of quizartinib may also cause some side effects, including low white blood cell counts, electrolyte imbalances, and elevated liver or muscle enzyme levels. Therefore, during treatment, doctors need to closely monitor the patient's health and adjust the treatment plan appropriately.

Overall, quizartinib provides a new treatment option for FLT3-ITD-positive AML patients, which is expected to significantly improve their prognosis and quality of life. With continued clinical research and accumulation of practical experience, quizartinib will play an increasingly critical role in the treatment of acute myeloid leukemia.

xa0

Reference materials:https://www.drugs.com/mtm/quizartinib.html